Nothing Special   »   [go: up one dir, main page]

IL284022A - Anti-transthyretin antibodies - Google Patents

Anti-transthyretin antibodies

Info

Publication number
IL284022A
IL284022A IL284022A IL28402221A IL284022A IL 284022 A IL284022 A IL 284022A IL 284022 A IL284022 A IL 284022A IL 28402221 A IL28402221 A IL 28402221A IL 284022 A IL284022 A IL 284022A
Authority
IL
Israel
Prior art keywords
transthyretin antibodies
transthyretin
antibodies
Prior art date
Application number
IL284022A
Other languages
Hebrew (he)
Other versions
IL284022B2 (en
IL284022B1 (en
Inventor
Yue Liu
Tarlochan Nijjar
Avijit Chakrabartty
Jeffrey N Higaki
Original Assignee
Prothena Biosciences Ltd
Univ Health Network
Yue Liu
Tarlochan Nijjar
Avijit Chakrabartty
Jeffrey N Higaki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd, Univ Health Network, Yue Liu, Tarlochan Nijjar, Avijit Chakrabartty, Jeffrey N Higaki filed Critical Prothena Biosciences Ltd
Priority claimed from PCT/IB2016/050415 external-priority patent/WO2016120810A1/en
Publication of IL284022A publication Critical patent/IL284022A/en
Publication of IL284022B1 publication Critical patent/IL284022B1/en
Publication of IL284022B2 publication Critical patent/IL284022B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL284022A 2015-12-11 2016-01-28 Anti-transthyretin antibodies IL284022B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562266556P 2015-12-11 2015-12-11
US201662109002P 2016-01-28 2016-01-28
PCT/IB2016/050415 WO2016120810A1 (en) 2015-01-28 2016-01-28 Anti-transthyretin antibodies

Publications (3)

Publication Number Publication Date
IL284022A true IL284022A (en) 2021-07-29
IL284022B1 IL284022B1 (en) 2023-05-01
IL284022B2 IL284022B2 (en) 2023-09-01

Family

ID=77163749

Family Applications (1)

Application Number Title Priority Date Filing Date
IL284022A IL284022B2 (en) 2015-12-11 2016-01-28 Anti-transthyretin antibodies

Country Status (1)

Country Link
IL (1) IL284022B2 (en)

Also Published As

Publication number Publication date
IL284022B2 (en) 2023-09-01
IL284022B1 (en) 2023-05-01

Similar Documents

Publication Publication Date Title
HK1253507A1 (en) Anti-ror1 antibodies
HK1256116A1 (en) Anti-lag-3 antibodies
HK1254836A1 (en) Anti-ror1 antibodies
IL253633B (en) Anti-transthyretin antibodies
GB201521391D0 (en) Antibodies
GB201521393D0 (en) Antibodies
HK1246804A1 (en) Tau-binding antibodies
GB201521382D0 (en) Antibodies
ZA201705662B (en) Anti-transthyretin antibodies
IL255323A0 (en) Anti-fcrn antibodies
HK1255056A1 (en) Anti-cd115 antibodies
SG11201706126WA (en) Anti-transthyretin antibodies
GB201509907D0 (en) Antibodies
GB201522394D0 (en) Antibodies
GB201503438D0 (en) Antibodies
IL284022A (en) Anti-transthyretin antibodies
GB201518728D0 (en) Antibodies
GB201515572D0 (en) Anti-LAG-3 antibodies
GB201515570D0 (en) Anti-LAG-3 antibodies
GB201514425D0 (en) Antibodies
GB201508437D0 (en) Antibodies
GB201508444D0 (en) Antibodies
GB201507541D0 (en) Antibodies
GB201504858D0 (en) Antibodies
GB201502591D0 (en) Antibodies